JLINX

Accelerating Research to
Transform Human Health

Learn more

About Us

Johnson & Johnson Innovation, JLINX is a multifaceted initiative in Europe designed to identify and nurture early-stage companies who are actively pursuing research with the potential to transform human health.

Accelerating early-stage transformative innovation

We catalyze scientific advances by offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem.

Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, Johnson & Johnson Innovation, JLINX fosters a creative start-up culture, provides access to select scientific talent and resources on the Janssen Campus and through the Johnson & Johnson Innovation network.

JLINX has a focus on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions.

Team

Johnson & Johnson Innovation, JLINX is a collaboration between Janssen Pharmaceutica NV and bioqube ventures, which will provide an experienced management team to run the day-to-day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

  • Tom Aelbrecht
    Head of the Janssen Campus Office
  • Kurt Hertogs
    Platform Innovation & Incubation Strategy Leader
  • Debora Dumont
    Managing director of Bioqube Ventures
  • Nico Vandervelpen
    Managing director of Bioqube Ventures
  • Close

    Tom Aelbrecht,
    MSc

    Head of the Janssen Campus Office

    Tom is Head of the Janssen Campus Office (JCO). The JCO was created as a platform to facilitate and implement the growth strategy of Janssen in Belgium. Through his active role in implementing and supporting JLINX, Tom helps to strengthen the innovative power of Janssen in Belgium and participates in the development of a competitive campus. His focus is on positioning Janssen in Belgium as a hub for collaboration, leading to innovative solutions for the patient. As a member of the Management Board he takes responsibility for the strategic pillars Open Innovation and Sustainability.

    Tom represents Janssen in several Boards of Directors of public organizations, and is also a strategic advisor to promising companies. Tom joined Johnson & Johnson in 1999 and held various positions with increasing responsibilities.

    Tom received his Masters degree in Computer Science from the University of Antwerp. In 2009, he obtained an Executive Master in Innovation & Entrepreneurship at the Vlerick Leuven Gent Management School. Tom is the owner of two patents.

    Email contact: taelbrec@its.jnj.com

  • Close

    Kurt Hertogs,
    PHD

    Platform Innovation & Incubation Strategy Leader

    Kurt Hertogs is currently Platform Innovation & Incubation Strategy Leader at the Johnson & Johnson Innovation Center in London. In this role, he is responsible for leading the implementation of the JLINX incubation initiative. He is working together with the JLINX management team and other stakeholders to identify transformative innovations and to provide entrepreneurs the opportunity to accelerate bringing their products to patients in need.

    Kurt started his professional career as a founding research director of Belgian biotech start-ups Tibotec and Virco and was involved in the discovery and pharmacological profiling of the anti-infective drugs Prezista, Intelence, Edurant, Incivo, Olysio and Sirturo, and the development of AntivirogramTM and VircoTypeTM diagnostic platforms. Today, these drugs are positively impacting and improving the lives of hundreds of thousands of HIV-, HCV-, or TB - infected people worldwide.

    After the acquisition of Tibotec-Virco NV by Johnson & Johnson in 2002 and prior to joining the London Innovation Center in 2013, Kurt led the European and Global Enabling Research Capabilities at Janssen R&D, helping to advance the discovery product portfolio across Janssen’s five strategic therapeutic areas.

    Kurt is a trained Pharmacist and holds a PhD in Pharmaceutical Sciences from the Catholic University of Leuven, Belgium.

    Email contact: khertog1@its.jnj.com

  • Close

    Debora Dumont,
    PhD

    Managing director of Bioqube Ventures

    Debora Dumont is managing director and cofounder of bioqube ventures. In 2016, bioqube ventures partnered with Johnson & Johnson Innovation to act as independent management team leading the new JLINX initiative. Through this role, bioqube ventures will be running the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.

    Debora previously served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions including amongst others XO1 (acquired by Johnson & Johnson), FFPharma, Complix and Therasolve. Prior to joining LRM, between 2007 and 2010, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (now LifeTechValley).

    Debora obtained her PhD in biomedical sciences at Hasselt University and holds a Masters degree in Bioscience Engineering from K.U. Leuven.

    Email contact: debbie@bioqubeventures.com

  • Close

    Nico Vandervelpen,
    MSc

    Managing director of Bioqube Ventures

    Nico Vandervelpen is managing director and cofounder of bioqube ventures. In 2016, bioqube ventures partnered with Johnson & Johnson Innovation to act as independent management team leading the new JLINX initiative. Through this role, bioqube ventures will be running the day-to- day operations of Johnson & Johnson, JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.

    Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.

    Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope. Nico holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.

    Email contact: nico@bioqubeventures.com

Approach

Johnson & Johnson Innovation, JLINX will provides entrepreneurs with opportunities to share ideas and collaborate with each other while accessing a unique combination of resources including investment, infrastructure, and access to relevant internal and external scientific, technical and business expertise.

Operating at the Nexus of Science and Business

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.

JLINX accelerates early-stage transformative innovation, including a focus on the human microbiome as well as broader life-science research.

Nurtured Independence

Investment in promising transformative innovation through Johnson & Johnson Innovation, JLINX is venture-based and the Johnson & Johnson Family of Companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.

Johnson & Johnson Innovation will works closely with Bioqube Ventures, which will provide an experienced incubator management team to run day-to-day operations, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

Agility with Scale

Our model combines internal expertise with external entrepreneurial skills creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.

Timeline

jlinx-timeline.jpg

JLINX is open to receive applications. Contact us to discuss opportunities to collaborate with you.

Contact us

News

  • S-Biomedic joins the JLINX Community

    Beerse, Belgium, February 9th 2017.

    S-Biomedic, an early stage biotech company focused on skin microbiome, has secured financing enabling the company to advance its lead product for acne patients.

    S-Biomedic has developed a method to directly modulate the skin microbiome, with applications in dermatology and the cosmetic industry. The skin microbiome, a habitat of billions of good and bad bacteria, contributes to conditions ranging from acne, eczema and rosacea to ageing. The company was founded by Veronika Oudova, Bernhard Pätzold and Marc Güell and is located at the JLINX facilities in Beerse, Belgium. 

  • Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions

    Cambridge, MA
    02 February 2017

    Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation

  • Caelus Health joins the JLINX Community

    Amsterdam, the Netherlands, January 26th 2017

    Caelus Health has secured EUR 2.5 million in a Series A investment round, enabling the company to advance its pipeline of microbiota-based products for early intervention in cardio-metabolic disease.

    Caelus Health is one of the first companies fully dedicated to the clinical development of microbiota-based products for early intervention in cardio-metabolic disease. Caelus was founded in 2014 by prof. Max Nieuwdorp (Academic Medical Centre, AMC, Amsterdam) and prof. Willem M. De Vos (Wageningen University), based on the initial work with fecal transplant studies in the AMC. 

Pages

Events

Contact Us

Make the Connection

JLINX is open to receive applications. We look forward to discussing opportunities to collaborate with you.

For general inquiries about JLINX, contact:
JLINX@ITS.JNJ.com

For investment inquiries, contact:
info@bioqubeventures.com

Telephone:
+32 (0) 14-621-500

Download the Johnson & Johnson
JLINX fact sheet.

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.